Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study

Inclusion Criteria: All subjects: * Provide written informed consent prior to the performance of any study-related procedures. * Be 18 to 65 years of age at screening. * Weigh within ± 25% of the ideal using the body mass index method. * Able to comply with all protocol requirements. Healthy Subjects: * Be healthy males or non-pregnant, non-breast-feeding healthy females. * Have an forced expiratory volume in one second (FEV1) of at least 80% of predicted or greater based on age, sex, height, and race based on European Community for Steel and Coal (ECSC) equations Subjects with Cystic Fibrosis: * Be chronically colonized with Pseudomonas aeruginosa . * Have a diagnosis of CF by documented sweat chloride of 60 mEq/L or greater by quantitative pilocarpine iontophoresis test (QPIT) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with CF. * Have an FEV1 of 25% or more of the predicted value, calculated using ECSC equations based on age, sex, height, and race. * Able to tolerate a 1-week washout interval with no inhaled tobramycin or other aminoglycoside treatment. * Be clinically stable in the opinion of the referring investigator at the CF unit. Exclusion Criteria: All subjects: * Participation in a clinical research study within the previous 1 month. * History of alcohol or drug abuse. * Positive result for drugs of abuse. * Regular alcohol consumption in males and females of more than 21 units…